DE60219888D1 - Antikörper zur modulierung der upa/upar interaktion und deren verwendungen - Google Patents

Antikörper zur modulierung der upa/upar interaktion und deren verwendungen

Info

Publication number
DE60219888D1
DE60219888D1 DE60219888T DE60219888T DE60219888D1 DE 60219888 D1 DE60219888 D1 DE 60219888D1 DE 60219888 T DE60219888 T DE 60219888T DE 60219888 T DE60219888 T DE 60219888T DE 60219888 D1 DE60219888 D1 DE 60219888D1
Authority
DE
Germany
Prior art keywords
upar
upa
modulating
antibodies
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219888T
Other languages
English (en)
Other versions
DE60219888T2 (de
Inventor
Francesco Blasi
Nicolai Sidenius
Massimo Resnati
Anna Mondino
Guido Poli
Massimo Alfano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND, Fondazione Centro San Raffaele del Monte Tabor filed Critical SAN RAFFAELE CENTRO FOND
Application granted granted Critical
Publication of DE60219888D1 publication Critical patent/DE60219888D1/de
Publication of DE60219888T2 publication Critical patent/DE60219888T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
DE60219888T 2001-01-25 2002-01-22 Antikörper zur modulierung der upa/upar interaktion und deren verwendungen Expired - Lifetime DE60219888T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26319801P 2001-01-25 2001-01-25
US263198P 2001-01-25
PCT/EP2002/000603 WO2002058714A2 (en) 2001-01-25 2002-01-22 Methods and agents modulating upa/upar activity

Publications (2)

Publication Number Publication Date
DE60219888D1 true DE60219888D1 (de) 2007-06-14
DE60219888T2 DE60219888T2 (de) 2008-01-17

Family

ID=23000794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219888T Expired - Lifetime DE60219888T2 (de) 2001-01-25 2002-01-22 Antikörper zur modulierung der upa/upar interaktion und deren verwendungen

Country Status (7)

Country Link
US (2) US7737256B2 (de)
EP (1) EP1365797B1 (de)
AT (1) ATE361096T1 (de)
AU (1) AU2002229721A1 (de)
DE (1) DE60219888T2 (de)
ES (1) ES2282397T3 (de)
WO (1) WO2002058714A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074891B2 (en) 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
CA2595935A1 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
WO2006094828A2 (en) * 2005-03-11 2006-09-14 Wilex Ag Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
WO2008104857A2 (en) * 2007-02-26 2008-09-04 Universite De Lausanne Method for predicting susceptibility of hiv infection
US20160169910A1 (en) * 2013-08-01 2016-06-16 Rush University Medical Center Non-Glycosylated suPar Biomarkers and Uses Thereof
US20220135669A1 (en) * 2018-09-28 2022-05-05 Rush University Medical Center suPAR and Prediction and Treatment of Acute Kidney Injury
CN113975381A (zh) * 2020-07-26 2022-01-28 刘建宁 尿激酶原及其变体在病毒引起的凝血疾病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033653T2 (de) * 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 Plasminogen-aktivator-rezeptor vom urokinasetyp
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
WO1996013160A1 (en) 1994-11-01 1996-05-09 New England Deaconess Hospital Use of urokinase-type plasminogen activators to inhibit hiv infectivity
WO1998042733A1 (en) * 1997-03-20 1998-10-01 Fondazione Centro San Raffaele Del Monte Tabor uPAR MIMICKING PEPTIDE
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
ATE368854T1 (de) 1999-11-25 2007-08-15 Jesper Eugen-Olsen Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten

Also Published As

Publication number Publication date
EP1365797B1 (de) 2007-05-02
US7737256B2 (en) 2010-06-15
WO2002058714A2 (en) 2002-08-01
US20110027285A1 (en) 2011-02-03
US20040115190A1 (en) 2004-06-17
DE60219888T2 (de) 2008-01-17
AU2002229721A1 (en) 2002-08-06
ES2282397T3 (es) 2007-10-16
ATE361096T1 (de) 2007-05-15
EP1365797A2 (de) 2003-12-03
WO2002058714A3 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
MEP31508A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY1118991T1 (el) Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
TW200514790A (en) Bispecific antibody substituting for functional protein
PL1641483T3 (pl) Białka fuzyjne
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
CO5690537A2 (es) Formas solidas de anticuerpos anti-egfr
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
NO20050063L (no) 2-heteroaryl karboksamider
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
CY1112621T1 (el) Clostridia νευροτοξινης για χρηση στη θεραπεια της ρινικης συμφορησης
DE60219888D1 (de) Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
DE69634412D1 (de) Regulierte gene und ihre verwendungen
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
WO2004039955A3 (en) Modulators of angiogenesis and tumorigenesis
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
ATE288763T1 (de) Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
SE0102147D0 (sv) New methods
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke

Legal Events

Date Code Title Description
8364 No opposition during term of opposition